Top drugmakers roll out cheaper semaglutide within a day of patent expiry, triggering a scramble for share in India's weight-loss and diabetes market ....
The generic drugmakers, with many more expected to make announcements, are eyeing a share of the market for Semaglutide in India, which is estimated to be $1 billion over the next couple of years ....
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug's patent expired, offering lower‑cost options for patients... .
Three major Indian drugmakers have introduced low-cost generic versions of Semaglutide injections following the expiry of its patent, expanding access for patients with Type 2 Diabetes and obesity.
<p>With the patent protection for Novo Nordisk’s best-selling medicine semaglutide expiring in India, at least eight Indian companies on Saturday launched cheaper, generic versions of the drug ...